These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 8031168

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Kampo medicines for the prevention of irinotecan-induced diarrhea in advanced non-small cell lung cancer].
    Mori K, Hirose T, Machida S, Tominaga K.
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1159-63. PubMed ID: 9679578
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat.
    Kase Y, Hayakawa T, Aburada M, Komatsu Y, Kamataki T.
    Jpn J Pharmacol; 1997 Dec; 75(4):407-13. PubMed ID: 9469647
    [Abstract] [Full Text] [Related]

  • 5. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T, Arioka H, Kunikane H, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Oshita F, Nishio M, Karato A.
    Cancer Res; 1994 May 15; 54(10):2636-42. PubMed ID: 8168091
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
    Takasuna K, Hagiwara T, Watanabe K, Onose S, Yoshida S, Kumazawa E, Nagai E, Kamataki T.
    Cancer Chemother Pharmacol; 2006 Oct 15; 58(4):494-503. PubMed ID: 16437251
    [Abstract] [Full Text] [Related]

  • 9. [CPT-11-induced diarrhea treated with indisetron hydrochloride--a case report].
    Kanbe M, Osada M.
    Gan To Kagaku Ryoho; 2005 Dec 15; 32(13):2145-7. PubMed ID: 16352947
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
    Michael M, Brittain M, Nagai J, Feld R, Hedley D, Oza A, Siu L, Moore MJ.
    J Clin Oncol; 2004 Nov 01; 22(21):4410-7. PubMed ID: 15514383
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
    Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E.
    J Clin Oncol; 1998 Aug 01; 16(8):2745-51. PubMed ID: 9704727
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].
    Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, Kudo K.
    Gan To Kagaku Ryoho; 2002 Jul 01; 29(7):1171-7. PubMed ID: 12145998
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.